Sage Therapeutics (SAGE) Financials

$6.86 -0.31 (-4.32%)

Closing price 04:00 PM Eastern

Extended Trading

$7.16 +0.30 (+4.37%)

As of 07:48 PM Eastern

Annual Income Statements for Sage Therapeutics

This table shows Sage Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-533	-541	-401
Consolidated Net Income / (Loss)	-533	-541	-401
Net Income / (Loss) Continuing Operations	-533	-541	-401
Total Pre-Tax Income	-533	-541	-401
Total Operating Income	-547	-580	-432
Total Gross Profit	7.69	86	41
Total Revenue	7.69	86	41
Operating Revenue	7.69	86	41
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	555	666	474
Selling, General & Admin Expense	228	275	216
Research & Development Expense	326	356	226
Other Operating Expenses / (Income)	0.81	2.16	9.44
Restructuring Charge	0.00	33	22
Total Other Income / (Expense), net	14	38	32
Interest & Investment Income	14	39	32
Other Income / (Expense), net	-	-0.38	0.03
Basic Earnings per Share	($8.98)	($9.05)	($6.59)
Weighted Average Basic Shares Outstanding	59.31M	59.84M	60.77M
Diluted Earnings per Share	($8.98)	($9.05)	($6.59)
Weighted Average Diluted Shares Outstanding	59.31M	59.84M	60.77M
Weighted Average Basic & Diluted Shares Outstanding	59.72M	60.11M	61.48M

This table shows Sage Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-137	-147	-147	-160	-202	-33	-108	-103	-94	-96	-62
Consolidated Net Income / (Loss)	-137	-147	-147	-160	-202	-33	-108	-103	-94	-96	-62
Net Income / (Loss) Continuing Operations	-137	-147	-147	-160	-202	-33	-108	-103	-94	-96	-62
Total Pre-Tax Income	-137	-147	-147	-160	-202	-33	-108	-103	-94	-96	-62
Total Operating Income	-141	-154	-155	-170	-212	-42	-118	-111	-101	-102	-67
Total Gross Profit	1.56	3.53	3.06	2.27	2.72	78	6.63	8.65	6.59	19	14
Total Revenue	1.74	2.86	3.29	2.47	2.72	78	7.90	8.65	12	13	14
Operating Revenue	1.74	2.86	3.29	2.47	2.72	78	7.90	8.65	12	13	14
Total Cost of Revenue	0.18	-0.67	0.23	0.21	0.00	-0.44	1.27	0.00	5.28	-6.55	0.00
Total Operating Expenses	143	157	159	173	215	120	124	120	108	122	82
Selling, General & Admin Expense	61	67	66	76	78	55	53	56	53	55	58
Research & Development Expense	82	89	93	97	102	64	72	63	55	37	23
Other Operating Expenses / (Income)	-	-	-	-	0.91	-	-	1.41	-	-	0.66
Restructuring Charge	0.00	-	-	-	34	-	-	-	0.00	-	0.51
Total Other Income / (Expense), net	4.16	6.76	8.83	10	10	9.08	9.20	8.43	7.64	6.43	5.24
Interest & Investment Income	4.13	6.79	8.83	10	10	9.47	9.20	8.43	7.64	6.40	5.22
Other Income / (Expense), net	0.03	-	-	-	-	-	-	-	-	-	0.02
Basic Earnings per Share	($2.31)	($2.47)	($2.46)	($2.68)	($3.37)	($0.54)	($1.80)	($1.70)	($1.53)	($1.56)	($1.01)
Weighted Average Basic Shares Outstanding	59.43M	59.31M	59.67M	59.77M	59.91M	59.84M	60.14M	60.54M	61.12M	60.77M	61.86M
Diluted Earnings per Share	($2.31)	($2.47)	($2.46)	($2.68)	($3.37)	($0.54)	($1.80)	($1.70)	($1.53)	($1.56)	($1.01)
Weighted Average Diluted Shares Outstanding	59.43M	59.31M	59.67M	59.77M	59.91M	59.84M	60.14M	60.54M	61.12M	60.77M	61.86M
Weighted Average Basic & Diluted Shares Outstanding	59.49M	59.72M	59.76M	59.88M	59.97M	60.11M	60.18M	61.05M	61.17M	61.48M	62.62M

This table details how cash moves in and out of Sage Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-132	-92	10
Net Cash From Operating Activities	-460	-541	-267
Net Cash From Continuing Operating Activities	-460	-541	-267
Net Income / (Loss) Continuing Operations	-533	-541	-401
Consolidated Net Income / (Loss)	-533	-541	-401
Depreciation Expense	1.12	1.39	1.03
Amortization Expense	5.85	-6.34	-6.48
Non-Cash Adjustments To Reconcile Net Income	66	79	59
Changes in Operating Assets and Liabilities, net	0.09	-73	79
Net Cash From Investing Activities	325	443	267
Net Cash From Continuing Investing Activities	325	443	267
Purchase of Property, Plant & Equipment	-0.94	-0.55	0.00
Purchase of Investments	-881	-595	-451
Sale and/or Maturity of Investments	1,207	1,038	718
Net Cash From Financing Activities	3.07	6.03	11
Net Cash From Continuing Financing Activities	3.07	6.03	11
Repurchase of Common Equity	0.00	0.00	-0.12
Issuance of Common Equity	3.11	6.93	11
Other Financing Activities, net	-0.04	-0.90	-0.40

This table details how cash moves in and out of Sage Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-6.68	-37	44	-85	27	-78	103	-73	-0.27	-20	-36
Net Cash From Operating Activities	-119	-127	-154	-132	-136	-120	-38	-80	-82	-67	-82
Net Cash From Continuing Operating Activities	-119	-127	-154	-132	-136	-120	-38	-80	-82	-67	-82
Net Income / (Loss) Continuing Operations	-137	-147	-147	-160	-202	-33	-108	-103	-94	-96	-62
Consolidated Net Income / (Loss)	-137	-147	-147	-160	-202	-33	-108	-103	-94	-96	-62
Depreciation Expense	0.28	0.29	0.32	0.33	0.33	0.41	0.34	0.31	0.26	0.13	0.11
Amortization Expense	1.07	-1.33	-3.18	-4.39	-4.95	6.18	-1.55	-1.94	-2.05	-0.94	-0.98
Non-Cash Adjustments To Reconcile Net Income	15	17	21	13	30	14	15	19	16	9.90	7.19
Changes in Operating Assets and Liabilities, net	2.54	4.61	-25	20	40	-108	57	5.35	-2.62	20	-26
Net Cash From Investing Activities	111	90	195	46	160	42	139	-0.39	81	47	46
Net Cash From Continuing Investing Activities	111	90	195	46	160	42	139	-0.39	81	47	46
Purchase of Property, Plant & Equipment	-0.36	-0.28	-0.23	-0.11	-0.33	0.11	0.00	-	-	-	0.00
Purchase of Investments	-251	-199	-157	-233	-70	-135	-62	-198	-102	-89	-88
Sale and/or Maturity of Investments	363	289	352	278	231	177	201	198	183	135	134
Net Cash From Financing Activities	1.23	0.03	2.67	0.85	2.77	-0.26	1.56	8.07	1.04	-0.00	0.15
Net Cash From Continuing Financing Activities	1.23	0.03	2.67	0.85	2.77	-0.26	1.56	8.07	1.04	-0.00	0.15
Repurchase of Common Equity	-	-	-	-	-	-	-	-	-	-	0.00
Issuance of Common Equity	1.24	0.03	3.30	0.86	2.77	-	1.56	8.19	1.44	-0.00	0.24
Other Financing Activities, net	-0.02	-0.00	-0.63	-0.01	-0.00	-0.26	-0.00	-0.00	-0.40	-0.00	-0.09

This table presents Sage Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,356	882	547
Total Current Assets	1,337	869	531
Cash & Equivalents	163	71	81
Restricted Cash	0.00	1.33	0.00
Short-Term Investments	1,110	682	423
Accounts Receivable	14	83	9.13
Prepaid Expenses	51	32	18
Plant, Property, & Equipment, net	2.90	1.92	0.89
Total Noncurrent Assets	17	11	15
Other Noncurrent Operating Assets	15	11	14
Other Noncurrent Nonoperating Assets	1.27	0.00	1.45
Total Liabilities & Shareholders' Equity	1,356	882	547
Total Liabilities	104	83	82
Total Current Liabilities	99	83	72
Accounts Payable	19	10	13
Accrued Expenses	73	67	58
Other Current Liabilities	7.64	5.17	1.32
Total Noncurrent Liabilities	4.59	0.00	11
Other Noncurrent Operating Liabilities	4.59	0.00	11
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,253	800	465
Total Preferred & Common Equity	1,253	800	465
Preferred Stock	0.00	0.00	0.00
Total Common Equity	1,253	800	465
Common Stock	3,291	3,370	3,436
Retained Earnings	-2,028	-2,570	-2,970
Treasury Stock	-0.40	-0.40	-0.40
Accumulated Other Comprehensive Income / (Loss)	-10	-0.81	0.24

This table presents Sage Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	1,486	1,221	1,082	950	768	697	622	470
Total Current Assets	1,465	1,203	1,064	933	755	687	605	454
Cash & Equivalents	200	207	121	149	173	100	100	45
Short-Term Investments	1,194	923	881	727	544	547	470	379
Accounts Receivable	18	15	15	23	11	9.94	15	11
Prepaid Expenses	53	59	46	35	27	29	20	20
Plant, Property, & Equipment, net	2.82	2.66	2.48	2.44	1.59	1.27	1.02	0.78
Total Noncurrent Assets	18	15	16	14	11	9.02	16	14
Other Noncurrent Operating Assets	17	13	14	13	9.07	9.02	16	13
Other Noncurrent Nonoperating Assets	1.27	1.27	1.33	1.33	1.50	0.00	0.00	1.45
Total Liabilities & Shareholders' Equity	1,486	1,221	1,082	950	768	697	622	470
Total Liabilities	106	88	98	133	62	69	71	60
Total Current Liabilities	100	85	97	133	62	69	60	50
Accounts Payable	7.08	12	9.28	11	6.48	8.65	7.13	5.44
Accrued Expenses	85	65	80	115	52	59	53	43
Other Current Liabilities	7.60	7.68	7.73	6.97	3.31	1.41	0.08	1.81
Total Noncurrent Liabilities	6.26	2.87	1.11	0.00	0.00	0.00	10	10
Other Noncurrent Operating Liabilities	6.26	2.87	1.11	0.00	-	-	10	10
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,380	1,133	984	817	706	628	552	410
Total Preferred & Common Equity	1,380	1,133	984	817	706	628	552	410
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,380	1,133	984	817	706	628	552	410
Common Stock	3,276	3,314	3,326	3,358	3,385	3,410	3,426	3,443
Retained Earnings	-1,881	-2,175	-2,335	-2,537	-2,678	-2,781	-2,875	-3,033
Treasury Stock	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40
Accumulated Other Comprehensive Income / (Loss)	-15	-5.09	-5.64	-3.74	-0.79	-0.69	0.90	0.14

This table displays calculated financial ratios and metrics derived from Sage Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	21.85%	1,024.84%	-52.30%
EBITDA Growth	-21.71%	-8.36%	25.19%
EBIT Growth	-18.68%	-6.08%	25.49%
NOPAT Growth	-18.68%	-6.01%	25.43%
Net Income Growth	-16.36%	-1.63%	26.01%
EPS Growth	-15.13%	-0.78%	27.18%
Operating Cash Flow Growth	-21.64%	-17.51%	50.57%
Free Cash Flow Firm Growth	-11.64%	-25.46%	54.06%
Invested Capital Growth	-45.62%	312.69%	-190.59%
Revenue Q/Q Growth	18.90%	661.85%	-61.24%
EBITDA Q/Q Growth	-6.74%	16.91%	-18.23%
EBIT Q/Q Growth	-5.48%	16.11%	-16.14%
NOPAT Q/Q Growth	-5.48%	16.17%	-16.15%
Net Income Q/Q Growth	-4.40%	17.45%	-18.68%
EPS Q/Q Growth	-4.06%	17.58%	-18.31%
Operating Cash Flow Q/Q Growth	-6.83%	1.35%	16.54%
Free Cash Flow Firm Q/Q Growth	-5.40%	-7.72%	28.34%
Invested Capital Q/Q Growth	-43.14%	174.13%	-118.64%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-7,025.94%	-676.86%	-1,061.49%
Operating Margin	-7,116.69%	-670.69%	-1,048.35%
EBIT Margin	-7,116.69%	-671.14%	-1,048.28%
Profit (Net Income) Margin	-6,931.88%	-626.32%	-971.48%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	97.41%	93.32%	92.67%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-3,403.73%	-14,293.22%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-3,390.36%	-14,277.67%
Return on Net Nonoperating Assets (RNNOA)	0.00%	3,350.95%	14,229.86%
Return on Equity (ROE)	-35.74%	-52.77%	-63.37%
Cash Return on Invested Capital (CROIC)	0.00%	-1,048.72%	0.00%
Operating Return on Assets (OROA)	-34.38%	-51.84%	-60.49%
Return on Assets (ROA)	-33.49%	-48.37%	-56.06%
Return on Common Equity (ROCE)	-35.74%	-52.77%	-63.37%
Return on Equity Simple (ROE_SIMPLE)	-42.53%	-67.73%	-86.15%
Net Operating Profit after Tax (NOPAT)	-383	-406	-303
NOPAT Margin	-4,981.68%	-469.49%	-733.84%
Net Nonoperating Expense Percent (NNEP)	-9.94%	-13.37%	-15.55%
Return On Investment Capital (ROIC_SIMPLE)	-30.57%	-50.77%	-65.08%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	2,962.52%	317.53%	524.74%
R&D to Revenue	4,243.60%	412.05%	547.72%
Operating Expenses to Revenue	7,216.69%	770.69%	1,148.35%
Earnings before Interest and Taxes (EBIT)	-547	-580	-432
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-540	-585	-438
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.81	1.63	0.71
Price to Tangible Book Value (P/TBV)	1.81	1.63	0.71
Price to Revenue (P/Rev)	295.22	15.03	8.05
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	12.11	0.00
Enterprise Value to Revenue (EV/Rev)	129.66	6.30	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.01	-0.99	-1.00
Leverage Ratio	1.07	1.09	1.13
Compound Leverage Factor	1.04	1.02	1.05
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	10.79	4.34	-6.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	13.47	10.51	7.42
Quick Ratio	12.96	10.11	7.17
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-376	-472	-217
Operating Cash Flow to CapEx	-49,096.69%	-97,754.97%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.08	0.06
Accounts Receivable Turnover	0.48	1.79	0.90
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	2.60	35.88	29.34
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	763.76	204.06	407.73
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	763.76	204.06	407.73
Capital & Investment Metrics	-	-	-
Invested Capital	-21	45	-41
Invested Capital Turnover	-0.43	7.25	19.48
Increase / (Decrease) in Invested Capital	-6.63	66	-86
Enterprise Value (EV)	997	545	-172
Market Capitalization	2,269	1,299	332
Book Value per Share	$21.05	$13.33	$7.60
Tangible Book Value per Share	$21.05	$13.33	$7.60
Total Capital	1,253	800	465
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-1,272	-755	-504
Capital Expenditures (CapEx)	0.94	0.55	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-35	32	-45
Debt-free Net Working Capital (DFNWC)	1,238	787	460
Net Working Capital (NWC)	1,238	787	460
Net Nonoperating Expense (NNE)	150	136	98
Net Nonoperating Obligations (NNO)	-1,274	-755	-506
Total Depreciation and Amortization (D&A)	6.98	-4.95	-5.45
Debt-free, Cash-free Net Working Capital to Revenue	-452.42%	37.11%	-108.46%
Debt-free Net Working Capital to Revenue	16,103.58%	909.84%	1,114.58%
Net Working Capital to Revenue	16,103.58%	909.84%	1,114.58%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($8.98)	($9.05)	($6.59)
Adjusted Weighted Average Basic Shares Outstanding	59.31M	59.84M	60.77M
Adjusted Diluted Earnings per Share	($8.98)	($9.05)	($6.59)
Adjusted Weighted Average Diluted Shares Outstanding	59.31M	59.84M	60.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.72M	60.11M	61.48M
Normalized Net Operating Profit after Tax (NOPAT)	-383	-383	-287
Normalized NOPAT Margin	-4,981.68%	-442.45%	-696.75%
Pre Tax Income Margin	-6,932.07%	-626.32%	-971.48%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.03%

This table displays calculated financial ratios and metrics derived from Sage Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	20.76%	74.42%	108.22%	64.82%	56.18%	2,622.45%	139.89%	249.80%	337.08%	-83.56%	77.97%
EBITDA Growth	-10.77%	-28.23%	-32.61%	-39.01%	-54.51%	77.10%	24.91%	35.29%	52.42%	-190.30%	42.55%
EBIT Growth	-8.06%	-22.64%	-26.19%	-32.75%	-49.77%	72.66%	24.31%	34.70%	52.23%	-142.89%	42.69%
NOPAT Growth	-8.09%	-22.64%	-26.19%	-32.75%	-49.74%	72.66%	24.31%	34.70%	52.23%	-142.89%	42.68%
Net Income Growth	-5.49%	-17.99%	-20.30%	-26.98%	-46.83%	77.77%	26.12%	35.85%	53.60%	-192.85%	42.65%
EPS Growth	-4.52%	-16.51%	-18.84%	-25.82%	-45.89%	78.14%	26.83%	36.57%	54.60%	-188.89%	43.89%
Operating Cash Flow Growth	-72.70%	-30.19%	-42.56%	-23.56%	-14.30%	5.84%	75.38%	38.84%	39.38%	44.31%	-116.03%
Free Cash Flow Firm Growth	3.26%	1.11%	-48.44%	-46.66%	-10.02%	5.41%	44.55%	24.61%	-10.32%	114.91%	30.65%
Invested Capital Growth	-68.33%	-45.62%	128.41%	-565.71%	-310.69%	312.69%	-717.32%	-2.51%	69.29%	-190.59%	-10.05%
Revenue Q/Q Growth	15.86%	64.69%	15.01%	-24.89%	9.78%	2,770.80%	-89.87%	9.52%	37.17%	7.96%	9.73%
EBITDA Q/Q Growth	-11.59%	-10.59%	-2.18%	-10.23%	-24.04%	83.61%	-235.07%	5.02%	8.80%	-0.01%	33.69%
EBIT Q/Q Growth	-10.16%	-8.80%	-1.02%	-9.64%	-24.28%	80.14%	-179.69%	5.42%	9.07%	-0.98%	34.01%
NOPAT Q/Q Growth	-10.18%	-8.78%	-1.02%	-9.64%	-24.28%	80.14%	-179.69%	5.42%	9.07%	-0.98%	33.99%
Net Income Q/Q Growth	-8.76%	-7.15%	0.22%	-9.19%	-25.76%	83.78%	-231.69%	5.19%	9.04%	-2.38%	35.04%
EPS Q/Q Growth	-8.45%	-6.93%	0.40%	-8.94%	-25.75%	83.98%	-233.33%	5.56%	10.00%	-1.96%	35.26%
Operating Cash Flow Q/Q Growth	-11.67%	-6.79%	-21.07%	14.42%	-3.31%	12.03%	68.35%	-112.62%	-2.40%	19.19%	-22.79%
Free Cash Flow Firm Q/Q Growth	-32.87%	-8.67%	-17.81%	13.79%	0.32%	6.57%	30.93%	-17.21%	-45.85%	112.63%	-421.27%
Invested Capital Q/Q Growth	-402.93%	-43.14%	110.75%	-960.31%	-210.26%	174.13%	-131.20%	-42.86%	7.04%	-118.64%	62.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.42%	123.39%	93.02%	91.71%	100.00%	100.56%	83.94%	100.00%	55.54%	151.08%	100.00%
EBITDA Margin	-8,056.58%	-5,409.99%	-4,806.50%	-7,054.04%	-7,970.18%	-45.51%	-1,504.59%	-1,304.90%	-867.61%	-803.74%	-485.71%
Operating Margin	-8,135.71%	-5,373.71%	-4,719.79%	-6,889.94%	-7,800.04%	-53.96%	-1,489.18%	-1,286.11%	-852.51%	-797.39%	-479.66%
EBIT Margin	-8,133.99%	-5,373.71%	-4,719.79%	-6,889.94%	-7,800.04%	-53.96%	-1,489.18%	-1,286.11%	-852.51%	-797.39%	-479.53%
Profit (Net Income) Margin	-7,896.66%	-5,137.78%	-4,457.44%	-6,480.40%	-7,423.79%	-41.95%	-1,372.86%	-1,188.51%	-788.06%	-747.33%	-442.39%
Tax Burden Percent	100.00%	100.00%	100.13%	100.03%	100.03%	99.14%	100.01%	99.99%	99.99%	100.01%	100.00%
Interest Burden Percent	97.08%	95.61%	94.32%	94.03%	95.15%	78.41%	92.18%	92.43%	92.45%	93.71%	92.26%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-273.84%	0.00%	0.00%	0.00%	-10,871.60%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	-273.52%	0.00%	0.00%	0.00%	-10,867.75%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	270.34%	0.00%	0.00%	0.00%	10,831.36%	0.00%
Return on Equity (ROE)	-31.74%	-35.74%	-40.53%	-47.55%	-59.72%	-3.50%	-54.72%	-55.28%	-49.34%	-40.24%	-63.53%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-18,275.38%	0.00%	0.00%	-1,048.72%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.81%	-25.96%	-30.31%	-53.25%	-72.68%	-4.17%	-136.41%	-140.57%	-115.39%	-46.01%	-36.75%
Return on Assets (ROA)	-29.91%	-24.82%	-28.63%	-50.09%	-69.17%	-3.24%	-125.75%	-129.90%	-106.67%	-43.12%	-33.90%
Return on Common Equity (ROCE)	-31.74%	-35.74%	-40.53%	-47.55%	-59.72%	-3.50%	-54.72%	-55.28%	-49.34%	-40.24%	-63.53%
Return on Equity Simple (ROE_SIMPLE)	-36.98%	0.00%	-49.21%	-60.10%	-80.32%	0.00%	-71.29%	-70.96%	-61.18%	0.00%	-86.47%
Net Operating Profit after Tax (NOPAT)	-99	-108	-109	-119	-148	-29	-82	-78	-71	-72	-47
NOPAT Margin	-5,695.00%	-3,761.60%	-3,303.86%	-4,822.95%	-5,460.03%	-37.77%	-1,042.43%	-900.28%	-596.76%	-558.17%	-335.76%
Net Nonoperating Expense Percent (NNEP)	-2.36%	-2.61%	-2.76%	-3.27%	-4.69%	-0.32%	-2.82%	-3.02%	-3.14%	-3.85%	-2.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.60%	-	-	-	-3.68%	-	-	-	-15.38%	-11.52%
Cost of Revenue to Revenue	10.58%	-23.39%	6.98%	8.29%	0.00%	-0.56%	16.06%	0.00%	44.46%	-51.08%	0.00%
SG&A Expenses to Revenue	3,535.48%	2,350.87%	1,994.78%	3,054.37%	2,877.10%	70.68%	665.33%	646.90%	448.31%	426.37%	409.52%
R&D to Revenue	4,689.65%	3,117.84%	2,818.03%	3,927.28%	3,752.54%	82.50%	907.80%	722.95%	459.74%	288.87%	161.84%
Operating Expenses to Revenue	8,225.13%	5,497.10%	4,812.81%	6,981.65%	7,900.04%	154.52%	1,573.12%	1,386.11%	908.05%	948.47%	579.66%
Earnings before Interest and Taxes (EBIT)	-141	-154	-155	-170	-212	-42	-118	-111	-101	-102	-67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-140	-155	-158	-175	-216	-35	-119	-113	-103	-103	-68
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.69	1.81	2.21	2.85	1.51	1.63	1.59	1.04	0.80	0.71	1.19
Price to Tangible Book Value (P/TBV)	1.69	1.81	2.21	2.85	1.51	1.63	1.59	1.04	0.80	0.71	1.19
Price to Revenue (P/Rev)	359.99	295.22	266.63	270.95	108.60	15.03	12.34	6.72	4.14	8.05	10.31
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	604.91	0.00	0.00	12.11	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	144.39	129.66	146.43	174.27	31.40	6.30	4.45	0.06	0.00	0.00	1.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.01	-1.00	-1.01	-1.03	-0.99	-1.01	-1.02	-1.06	-1.00	-1.03
Leverage Ratio	1.06	1.07	1.06	1.08	1.11	1.09	1.08	1.10	1.15	1.13	1.11
Compound Leverage Factor	1.03	1.02	1.00	1.01	1.06	0.86	1.00	1.02	1.06	1.06	1.02
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	12.20	11.74	15.36	14.76	2.11	6.36	6.72	0.77	-2.04	-4.71	-3.48
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	14.70	13.47	14.21	10.99	7.02	10.51	12.22	9.95	10.02	7.42	9.13
Quick Ratio	14.17	12.96	13.51	10.51	6.76	10.11	11.77	9.51	9.67	7.17	8.73
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-93	-101	-119	-103	-102	-96	-66	-77	-113	14	-46
Operating Cash Flow to CapEx	-32,655.22%	-45,011.35%	-68,303.11%	-117,426.79%	-41,422.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.01	0.01	0.01	0.08	0.09	0.11	0.14	0.06	0.08
Accounts Receivable Turnover	0.30	0.48	0.54	0.53	0.55	1.79	7.14	7.77	5.69	0.90	4.46
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.26	2.60	3.42	3.83	4.31	35.88	42.87	51.81	61.48	29.34	40.12
Accounts Payable Turnover	0.03	0.00	0.00	0.00	0.00	0.00	0.11	0.09	0.67	0.00	0.00
Days Sales Outstanding (DSO)	1,203.67	763.76	675.76	682.98	658.74	204.06	51.13	46.98	64.12	407.73	81.76
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	10,565.32	0.00	0.00	0.00	0.00	0.00	3,292.03	3,924.19	545.29	0.00	0.00
Cash Conversion Cycle (CCC)	-9,361.65	763.76	675.76	682.98	658.74	204.06	-3,240.90	-3,877.21	-481.17	407.73	81.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-15	-21	2.28	-20	-61	45	-14	-20	-19	-41	-15
Invested Capital Turnover	-0.55	-0.43	-3.28	-0.92	-0.30	7.25	-15.48	-4.91	-2.68	19.48	-3.21
Increase / (Decrease) in Invested Capital	-6.00	-6.63	10	-17	-46	66	-16	-0.49	42	-86	-1.41
Enterprise Value (EV)	933	997	1,376	1,807	356	545	405	5.45	-130	-172	65
Market Capitalization	2,327	2,269	2,506	2,810	1,232	1,299	1,124	654	441	332	489
Book Value per Share	$23.23	$21.05	$18.97	$16.47	$13.64	$13.33	$11.74	$10.44	$9.04	$7.60	$6.67
Tangible Book Value per Share	$23.23	$21.05	$18.97	$16.47	$13.64	$13.33	$11.74	$10.44	$9.04	$7.60	$6.67
Total Capital	1,380	1,253	1,133	984	817	800	706	628	552	465	410
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,394	-1,272	-1,130	-1,003	-876	-755	-718	-648	-570	-504	-424
Capital Expenditures (CapEx)	0.36	0.28	0.23	0.11	0.33	-0.11	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-35	-11	-35	-76	32	-25	-30	-26	-45	-19
Debt-free Net Working Capital (DFNWC)	1,365	1,238	1,119	967	800	787	694	618	545	460	405
Net Working Capital (NWC)	1,365	1,238	1,119	967	800	787	694	618	545	460	405
Net Nonoperating Expense (NNE)	38	39	38	41	53	3.25	26	25	23	24	15
Net Nonoperating Obligations (NNO)	-1,395	-1,274	-1,131	-1,004	-877	-755	-720	-648	-570	-506	-425
Total Depreciation and Amortization (D&A)	1.35	-1.04	-2.86	-4.06	-4.62	6.59	-1.22	-1.63	-1.79	-0.81	-0.87
Debt-free, Cash-free Net Working Capital to Revenue	-436.60%	-452.42%	-115.34%	-341.30%	-667.84%	37.11%	-27.13%	-31.22%	-24.35%	-108.46%	-40.41%
Debt-free Net Working Capital to Revenue	21,123.41%	16,103.58%	11,904.08%	9,326.20%	7,052.04%	909.84%	761.72%	635.28%	511.83%	1,114.58%	853.72%
Net Working Capital to Revenue	21,123.41%	16,103.58%	11,904.08%	9,326.20%	7,052.04%	909.84%	761.72%	635.28%	511.83%	1,114.58%	853.72%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.31)	($2.47)	($2.46)	($2.68)	($3.37)	($0.54)	($1.80)	($1.70)	($1.53)	($1.56)	($1.01)
Adjusted Weighted Average Basic Shares Outstanding	59.43M	59.31M	59.67M	59.77M	59.91M	59.84M	60.14M	60.54M	61.12M	60.77M	61.86M
Adjusted Diluted Earnings per Share	($2.31)	($2.47)	($2.46)	($2.68)	($3.37)	($0.54)	($1.80)	($1.70)	($1.53)	($1.56)	($1.01)
Adjusted Weighted Average Diluted Shares Outstanding	59.43M	59.31M	59.67M	59.77M	59.91M	59.84M	60.14M	60.54M	61.12M	60.77M	61.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.49M	59.72M	59.76M	59.88M	59.97M	60.11M	60.18M	61.05M	61.17M	61.48M	62.62M
Normalized Net Operating Profit after Tax (NOPAT)	-99	-108	-109	-119	-125	-29	-82	-78	-71	-72	-47
Normalized NOPAT Margin	-5,695.00%	-3,761.60%	-3,303.86%	-4,822.95%	-4,594.07%	-37.77%	-1,042.43%	-900.28%	-596.76%	-558.17%	-333.21%
Pre Tax Income Margin	-7,896.66%	-5,137.57%	-4,451.73%	-6,478.74%	-7,421.76%	-42.31%	-1,372.70%	-1,188.69%	-788.14%	-747.24%	-442.39%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.03%	-0.03%	-0.03%	-0.03%

Frequently Asked Questions About Sage Therapeutics' Financials

When does Sage Therapeutics's financial year end?

According to the most recent income statement we have on file, Sage Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Sage Therapeutics' net income changed over the last 2 years?

Sage Therapeutics' net income appears to be on a downward trend, with a most recent value of -$400.67 million in 2024, falling from -$532.78 million in 2022. The previous period was -$541.49 million in 2023. Check out Sage Therapeutics' forecast to explore projected trends and price targets.

What is Sage Therapeutics's operating income?

Sage Therapeutics's total operating income in 2024 was -$432.37 million, based on the following breakdown:

Total Gross Profit: $41.24 million
Total Operating Expenses: $473.61 million

How has Sage Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Sage Therapeutics' total revenue changed from $7.69 million in 2022 to $41.24 million in 2024, a change of 436.6%.

How much debt does Sage Therapeutics have?

Sage Therapeutics' total liabilities were at $82.13 million at the end of 2024, a 0.7% decrease from 2023, and a 20.9% decrease since 2022.

How much cash does Sage Therapeutics have?

In the past 2 years, Sage Therapeutics' cash and equivalents has ranged from $70.99 million in 2023 to $162.70 million in 2022, and is currently $81.02 million as of their latest financial filing in 2024.

How has Sage Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Sage Therapeutics' book value per share changed from 21.05 in 2022 to 7.60 in 2024, a change of -63.9%.

Related Companies

This page (NASDAQ:SAGE) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sage Therapeutics (SAGE) Financials

Frequently Asked Questions About Sage Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sage Therapeutics (SAGE) Financials

Annual Income Statements for Sage Therapeutics

Quarterly Income Statements for Sage Therapeutics

Annual Cash Flow Statements for Sage Therapeutics

Quarterly Cash Flow Statements for Sage Therapeutics

Annual Balance Sheets for Sage Therapeutics

Quarterly Balance Sheets for Sage Therapeutics

Annual Metrics and Ratios for Sage Therapeutics

Quarterly Metrics and Ratios for Sage Therapeutics

Frequently Asked Questions About Sage Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools